SCHEMBL4069308

SCHEMBL4069308

Cn1c(-c2ccc(Cl)cc2)nc2c(Cl)ncnc21

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 14/20 0.60
ADORA1 P30542 14/20 0.60
ADORA2A P29274 13/20 0.60
ADORA2B P29275 9/20 0.52
PI4KA P42356 1/20 0.52
PI4K2B Q8TCG2 1/20 0.52
PI4K2A Q9BTU6 1/20 0.52
PI4KB Q9UBF8 1/20 0.52
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
USP2 O75604 2/20 0.41
CYP1A2 P05177 1/20 0.41
TSHR P16473 1/20 0.41
TP53 P04637 1/20 0.41
MAPK1 P28482 1/20 0.41
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4062627 0.91 ADORA3 (0.55) ADORA3ADORA1ADORA2AADORA2BPI4KA
SCHEMBL4066247 0.88 ADORA3 (0.57) ADORA3ADORA1ADORA2AADORA2BPI4KA
SCHEMBL4067321 0.88 ADORA3 (0.57) ADORA3ADORA1ADORA2AADORA2BPI4KA
SCHEMBL783764 0.88 ADORA3 (0.68) ADORA3ADORA1ADORA2AADORA2BPI4KA
SCHEMBL6659013 0.85 ADORA3 (0.48) ADORA3ADORA1ADORA2AADORA2BPI4KA
SCHEMBL4058506 0.85 ADORA3 (0.59) ADORA3ADORA1ADORA2AADORA2BPI4KA
SCHEMBL4064370 0.83 ADORA1 (0.60) ADORA3ADORA1ADORA2AADORA2BPI4KA
SCHEMBL6666123 0.83 PIK3CD (0.51) ADORA3ADORA1ADORA2AADORA2BPI4KA
SCHEMBL6662360 0.83 ADORA3 (0.46) ADORA3ADORA1ADORA2AADORA2BPI4KA
SCHEMBL19426740 0.83 ADORA3 (0.47) ADORA3ADORA1ADORA2AADORA2BPI4KA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7517888-B2 e.g. cyclopentyl(9-ethyl-8-phenylpurin-6-yl)amine; diuretic; heart failure, chronic renal disease, cirrhosis CV THERAPEUTICS, INC. (US) 2009-04-14 US disclosed
EP-1751159-A2 PURINE DERIVATIVES AS A1 ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2007-02-14 EP disclosed
WO-2005105803-A2 PURINE DERIVATIVES AS A1 ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2005-11-10 WO disclosed
US-20050245546-A1 A1 adenosine receptor antagonists CV THERAPEUTICS, INC. 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245546-A1 A1 adenosine receptor antagonists ADORA1, ADORA2A, ADORA3 ADORA3 3/4885ADORA1 1/4885ADORA2A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.